Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed and treated each year, yet 10%–20% continue to experience fatigue, pain, or cognitive difficulties after antibiotics, underscoring a persistent diagnostic gap. New findings show that immune responses to specific lipids could support earlier detection and help identify patients with ongoing symptoms despite treatment.

Tufts University School of Medicine (Boston, MA, USA) researchers evaluated anti-lipid antibodies as candidate biomarkers for Borrelia burgdorferi infection. Building on prior work, the team focused on antibodies that target lipids the bacteria acquires from its human host. Unlike conventional antibody responses that may take weeks to develop and linger for years, these anti-lipid signals were assessed for their appearance during acute disease and their decline following effective therapy.

The study analyzed blood samples from 199 individuals diagnosed with Lyme disease, including some with symptoms that persisted months to years after treatment. Antibody levels were tracked over time and compared with samples from healthy volunteers and from patients with conditions that can resemble post-treatment Lyme disease syndrome (PTLDS), including lupus, multiple sclerosis, fibromyalgia, long COVID, and chronic fatigue syndrome.

Multiple analyses identified three anti-lipid antibodies elevated during infection. Two—anti-phosphatidic acid (αPA) and anti-phosphatidylserine (αPS)—were increased at diagnosis, including in some patients who had not yet tested positive on standard assays, suggesting potential utility for earlier case identification. Elevated αPS levels months after treatment were more common among patients with persistent symptoms, and this signal was largely absent in the comparison groups with other autoimmune or chronic illnesses.

The study published in Infection and Immunity on June 30, 2026. Investigators emphasized that the markers are not ready for clinical use; larger studies are needed to determine diagnostic accuracy and prognostic value. A large, multi-institution trial led by Tufts is now following patients for up to 15 months after a Lyme diagnosis to evaluate whether anti-lipid antibodies can reliably flag early infection and distinguish those who develop prolonged symptoms.

Related Links
Tufts University School of Medicine